Severe Constipation on Mounjaro: What the Evidence Says and When to Act

What the trial data actually recorded about constipation frequency and severity

The SURMOUNT-1 trial (the pivotal 72-week study published in the New England Journal of Medicine) found constipation to be among the four most commonly reported gastrointestinal events across all tirzepatide doses, sitting alongside nausea, diarrhoea and vomiting. Rates varied by dose: constipation was more frequently noted at higher maintenance doses, consistent with the expectation that a stronger slowing of gastric emptying produces a greater effect on bowel transit time. The majority of gastrointestinal events in the trial were graded mild to moderate and were most concentrated in the early weeks after starting or after a dose increase.

The NHS medicines information for tirzepatide lists constipation as a common side effect (meaning it affects somewhere between one in ten and one in one hundred people) and notes that it can range in intensity. For a proportion of those people, it tips from inconvenient into genuinely painful or disruptive. Can Mounjaro cause severe constipation? The evidence says yes, for a minority of users, particularly in the first few months or after a dose step up. If you are finding this difficult, our page on Mounjaro constipation covers what to expect and how to manage it in detail.

If you want to read more about the broader pattern of bowel changes tirzepatide can cause, our page on whether Mounjaro causes constipation covers the mechanism in more detail.

Why tirzepatide slows the gut and what that means in practice

Tirzepatide acts on two gut-hormone receptors, GIP and GLP-1, both of which are involved in the pace at which food leaves the stomach. Slower gastric emptying is not a side effect in the colloquial sense, it is part of the intended mechanism, reducing appetite by keeping food in the stomach longer. The downstream consequence is that transit through the rest of the gut can also slow, giving the colon more time to absorb water from stool. If you are curious about the pharmacology behind this, our page on how Mounjaro causes constipation explains the process in plain terms.

On a practical level, two variables have a meaningful influence on this: fluid intake and dietary fibre. When appetite falls on treatment, total food volume drops, and with it the natural fibre and fluid that help keep bowel movements regular. Some people find that keeping a glass of water next to their Mounjaro pen in the fridge door serves as a small but useful reminder, the pen is a prompt, the water a habit.

Gentle physical activity also supports bowel motility, and this matters during a period when people are often eating less and moving differently. A pharmacist or prescriber can advise on specific approaches, including whether a short course of an osmotic laxative is appropriate for your situation. Our page on managing constipation on Mounjaro goes through the practical options in full.

When to get medical help for constipation on Mounjaro

Most constipation on tirzepatide resolves with time and the practical measures above. But some presentations need prompt clinical assessment, and it is worth being clear about what those are.

Contact a healthcare professional the same day if you experience severe abdominal pain alongside constipation, particularly pain that spreads to your back, this combination can occasionally indicate a more serious problem requiring assessment. Similarly, if you have not had a bowel movement for more than a week despite trying simple remedies, or if constipation is accompanied by vomiting, significant bloating, or blood in the stool, those symptoms deserve a call to your GP or, out of hours, NHS 111 rather than a wait-and-see approach.

The MHRA's Drug Safety Update communications for GLP-1 receptor agonist medicines note that gastrointestinal events, while usually self-limiting, can in some cases contribute to dehydration, particularly when constipation alternates with diarrhoea or nausea. Dehydration compounds constipation and can place strain on the kidneys, so maintaining fluid intake during any gastrointestinal episode is not optional. You can also explore the wider picture of severe side effects of Mounjaro and what warrants urgent attention.

If you are unsure whether your symptoms are within the expected range, reporting them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk contributes to the ongoing safety monitoring of tirzepatide. You do not need a clinical opinion before submitting a report.

Starting a conversation about side effects before treatment begins

A question our prescribers hear regularly is whether someone's existing bowel habits (perhaps a tendency towards slower digestion or irritable bowel syndrome) makes them a poor candidate for tirzepatide. The honest answer is that it depends on the full picture, and it is exactly the kind of detail that a clinical consultation is designed to surface.

At nume, every person's responses are read personally by a GPhC-registered prescriber, not processed automatically, before any decision is made. Side effects like constipation come into that assessment: how likely they are for you, how they can be managed, and what to watch for. If constipation does become difficult during treatment, aftercare is available seven days a week. For anyone considering Mounjaro for weight management, the Mounjaro overview page explains the full treatment picture, and our free consultation is the place to speak to our prescribers about suitability and side effects directly.